Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Rilvegostomig - Astrazeneca

Next Previous
X
Search
Drug Profile

Rilvegostomig - Astrazeneca

Alternative Names: AZD-2936

Latest Information Update: 07 Aug 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator AstraZeneca
  • Developer AstraZeneca; Daiichi Sankyo Company; Presage Biosciences
  • Class Antineoplastics; Bispecific antibodies; Immunotherapies
  • Mechanism of Action Antibody-dependent cell cytotoxicity; Programmed cell death 1 receptor antagonists; T lymphocyte stimulants; TIGIT protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Biliary cancer; Non-small cell lung cancer
  • Phase II Adenocarcinoma; Gastric cancer; Liver cancer; Solid tumours
  • Phase 0 Squamous cell cancer

Most Recent Events

  • 05 Aug 2024 Phase-I development for Non-small cell lung cancer (Combination therapy, Late-stage disease, Metastatic disease, Second-line therapy or greater) is still ongoing in Belgium, France, Japan, Poland, Spain, Taiwan, Turkey and USA (IV), (NCT04612751)
  • 05 Aug 2024 AstraZeneca announces intention to submit regulatory application for Biliary cancer (Adjunctive therapy) in 2025 or later
  • 21 Jun 2024 AstraZeneca plans phase-III DESTINY-BTC01 trial for Biliary cancer (Combination therapy, Unresectable/Inoperable, Late-stage disease, Metastatic disease, First-line therapy) in Austria, Belgium, Brazil, Canada, Germany, Japan, South Korea, Netherlands and Taiwan(IV) in June 2024 , (NCT06467357)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top